Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

EQRX

EQRx (EQRX)

EQRx Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:EQRX
日付受信時刻ニュースソース見出しコード企業名
2023/11/2106 : 00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:EQRXEQRx Inc
2023/11/2014 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EQRXEQRx Inc
2023/11/2014 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EQRXEQRx Inc
2023/11/2014 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EQRXEQRx Inc
2023/11/1006 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQRXEQRx Inc
2023/11/1006 : 05Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:EQRXEQRx Inc
2023/11/1006 : 04Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:EQRXEQRx Inc
2023/11/1006 : 03Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EQRXEQRx Inc
2023/11/1006 : 01Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EQRXEQRx Inc
2023/11/1006 : 01Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:EQRXEQRx Inc
2023/11/0923 : 29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQRXEQRx Inc
2023/11/0901 : 30GlobeNewswire Inc.Revolution Medicines and EQRx Stockholders Approve EQRx AcquisitionNASDAQ:EQRXEQRx Inc
2023/11/0706 : 10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EQRXEQRx Inc
2023/11/0121 : 02Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EQRXEQRx Inc
2023/11/0120 : 59Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:EQRXEQRx Inc
2023/11/0120 : 57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQRXEQRx Inc
2023/08/1621 : 07Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:EQRXEQRx Inc
2023/08/0906 : 29Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:EQRXEQRx Inc
2023/08/0906 : 20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EQRXEQRx Inc
2023/08/0405 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQRXEQRx Inc
2023/08/0205 : 38Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:EQRXEQRx Inc
2023/08/0205 : 32Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:EQRXEQRx Inc
2023/08/0205 : 31Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:EQRXEQRx Inc
2023/08/0205 : 29Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:EQRXEQRx Inc
2023/08/0120 : 25Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:EQRXEQRx Inc
2023/08/0120 : 19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQRXEQRx Inc
2023/08/0120 : 00GlobeNewswire Inc.Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional CapitalNASDAQ:EQRXEQRx Inc
2023/07/0407 : 29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQRXEQRx Inc
2023/05/0906 : 06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:EQRXEQRx Inc
2023/05/0905 : 01GlobeNewswire Inc.EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial ResultsNASDAQ:EQRXEQRx Inc
 Showing the most relevant articles for your search:NASDAQ:EQRX